January 20, 2021 8:13am
Markets will take a back seat to inauguration, a listening day
Pre-open indication: 8 SELLs and 3 BUYs
What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
Dow futures are UP +0.14% (+43 points), S&P futures are UP +0.38% (+15 points) and NASDAQ futures are UP +0.82% (+107 points)
Stock futures slowly gaining on Wednesday,
European stocks advanced with the pan-European Stoxx 600 climbing +0.6% in early trading,
Asia-Pacific markets were mixed as investors reacted to the release of China’s latest benchmark lending rate with MSCI’s broadest index of Asia-Pacific shares gaining +0.97%.
Biden will be the 46th president of the United States shortly after noon ET while the week started-out with modest gains.
One of the biggest issues of present time: over 31.1 million doses have been across the country, only 12.3 million people have been inoculated?
- With a new science advisor from Boston’s biotech hub (Eric Lander, founding director of the Broad Institute of MIT and Harvard. A geneticist, molecular biologist, and mathematician, who has played a pioneering role in all aspects of the reading, understanding, and biomedical application of the human genome) should wave the flag for our sector in next years
Tuesday’s evening’s recap: RegMed Investors’ (RMi) closing bell: “rebound follows decline and a holiday” … https://www.regmedinvestors.com/articles/11726
- The Nasdaq closed UP +198.68 points (+1.53%);
- The IBB closed up +1.93% and XBI closed up +1.64%;
- Sector volume was MODERATE with 5 of the 18-upside having higher than the 3-month average volume with the increased volume of 7 of 14-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -1.10 points or -4.52% at 23.24;
- Tuesday’s percentage (%) of the 18-upside were +0.63% (FATE) to +15.57% (BSTG) while the 14-downside ranges from -0.07% (KDNY) to -6.64% (SLDB);
- 8 positive, 3 negative closes and 1 holiday, so far
Companies in my headlights – It’s your decision; I provide an idea and context:
Biostage (BSTG) closed up +$0.06 to $1.22 with 8,637 shares traded after Thursday’s -$0.02 to $1.16 with 295 shares traded after Wednesday’s -$0.00 to $1.18 with 411 shares traded, Tuesday’s $1.18 with 3,500 shares traded and last Monday’s $1.16 with 3,202 shares traded. Reiterating the WHY bottom-line questions:
- Question#1: WHY and WOW the number of shares traded (not for years) on Tuesday – 18,420 to initiate a “spasm” up-lift of +$0.19 or +15.57% to $1.41?
- Question#2: WHO is "propping or pumping" and WHICH “investor” is “stimulating” the volume?
- Question#3: Does it have anything to do with a 52-week low of $0.80 as well as a high of $4.88, a current share price of $1.22 following the last private placement priced at $4.00?
- Question#4: Is there a desperateness to warrants exercisable for an aggregate of 122,554 shares of common stock - their only form of raising capital.
- Question#5: Don’t U.S. public shareholders deserve accountability! DST capital resides in BSTG’s building space, WHAT does or WILL RSM US LLP do to correlate the “cozy” relationship?
- Questions#6: WILL the coming RSM US LLP’s audit review and define the inter (between) and intra (within or inside) relationship of DST Capital for legality? It’s still a question of connectivity with Dixintong Technology Group in China?
SELL into Strength:
Fate Therapeutics (FATE) closed up +$0.72 to $114.31 after Friday’s -$3.81 to $113.59, Thursday’s $117.40, Wednesday’s $113.29 and last Tuesday’s $112.05, with a positive +$0.25 or +0.21% aftermarket indication;
Intellia therapeutics (NTLA) closed up +$1.79 to $93.68 after Friday’s $81.89, Thursday’s $83.30, Wednesday’s $76.01 and last Tuesday’s $75.69 with a positive +$1.22 or +1.46% aftermarket indication
bluebird bio (BLUE) closed down -$1.02 to $49.51 after Friday’s $50.53, Thursday’s $51.85, Wednesday’s $49.49 and last Tuesday’s $52.33 with a positive +$0.49 or -0.99% aftermarket indication;
CRISPR Therapeutics (CRSP) closed down -$1.59 to $198.29 after Friday’s $199.88, Thursday’s $210.04, Wednesday’s $193.84 and last Tuesday’s $190.34 with a positive +$2.71 or +1.37% aftermarket indication;
Pluristem (PSTI) closed down -$0.17 to $7.87 after Friday’s -$0.10 to $8.04, Thursday’s $8.14, Wednesday’s $8.10 and last Tuesday’s $8.31 with a positive +$0.13 or +1.65% aftermarket indication;
SELL post offering announcement:
Editas Medicine (EDIT) closed down -$4.03 to $72.11 after an announcement of a proposed 3.5 million share offering with a negative -$1.11 or -0.615 aftermarket indication;
SELL with aftermarket indication:
Homology Medicine (FIXX) closed up +$0.29 to $13.23 after Friday’s $12.94, Thursday’s $13.17 Wednesday’s $12.32 and last Tuesday’s $12.62 with a negative -$0.21 or -1.59% aftermarket indication;
Ionis Pharmaceuticals (IONS) closed down -$0.25 to $61.03 after Friday’s $61.28, Thursday’s $61.35, Wednesday’s $59.65 and last Tuesday’s $59.15 with a negative -$0.78 or -1.28% aftermarket indication;
Mesoblast (MESO) closed down -$0.27 to $9.45 after Friday’s -$0.11 to $9.72, Thursday’s $9.83, Wednesday’s $10.14 and last Tuesday’s $10.24 with a negative -$0.25 or -2.65% aftermarket (Friday) indication;
The BOTTOM LINE: it’s time for decency … a logjam on Capitol Hill awaits president (elect) Biden.
“Our” sector’s earnings LPS (loss-per-share) season Is about to begin. Investors are considering whether they should ignore and wait for Q2.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.